Immune checkpoint inhibitors (ICPIs) targeting either the programmed cell death protein 1 (PD-1, e.g., nivolumab, pembrolizumab) or its ligand (PD-L1; e.g., durvalumab, atezolizumab) have recently shown promising efficacy across several tumour types [5]. Here, PDCD1 is linked to neoplasm.